Biogen Inc - Asset Resilience Ratio
Biogen Inc (BIIB) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biogen Inc (BIIB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1994–2025)
This chart shows how Biogen Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Biogen Inc (BIIB) total assets.
Liquid Assets Composition Over Time
This chart breaks down Biogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BIIB strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biogen Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biogen Inc Industry Peers by Asset Resilience Ratio
Compare Biogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422 |
Drug Manufacturers - General | 4.41% |
Annual Asset Resilience Ratio for Biogen Inc (1994–2025)
The table below shows the annual Asset Resilience Ratio data for Biogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.74% | $807.20 Million | $29.44 Billion | -- |
| 2024-12-31 | 0.00% | $0.00 | $28.05 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $26.84 Billion | -- |
| 2022-12-31 | 6.00% | $1.47 Billion | $24.55 Billion | -0.45pp |
| 2021-12-31 | 6.45% | $1.54 Billion | $23.88 Billion | +1.26pp |
| 2020-12-31 | 5.19% | $1.28 Billion | $24.62 Billion | -0.54pp |
| 2019-12-31 | 5.74% | $1.56 Billion | $27.23 Billion | -3.41pp |
| 2018-12-31 | 9.15% | $2.31 Billion | $25.29 Billion | +0.21pp |
| 2017-12-31 | 8.94% | $2.12 Billion | $23.65 Billion | -2.29pp |
| 2016-12-31 | 11.23% | $2.57 Billion | $22.88 Billion | +0.36pp |
| 2015-12-31 | 10.87% | $2.12 Billion | $19.50 Billion | +6.40pp |
| 2014-12-31 | 4.47% | $640.46 Million | $14.32 Billion | -0.75pp |
| 2013-12-31 | 5.23% | $620.17 Million | $11.86 Billion | -5.98pp |
| 2012-12-31 | 11.20% | $1.13 Billion | $10.13 Billion | -1.79pp |
| 2011-12-31 | 13.00% | $1.18 Billion | $9.05 Billion | +7.46pp |
| 2010-12-31 | 5.54% | $448.15 Million | $8.09 Billion | -2.44pp |
| 2009-12-31 | 7.97% | $681.84 Million | $8.55 Billion | -0.86pp |
| 2008-12-31 | 8.83% | $749.03 Million | $8.48 Billion | +2.76pp |
| 2007-12-31 | 6.07% | $523.84 Million | $8.63 Billion | +3.25pp |
| 2006-12-31 | 2.82% | $241.31 Million | $8.55 Billion | -0.56pp |
| 2005-12-31 | 3.38% | $282.58 Million | $8.37 Billion | -5.88pp |
| 2004-12-31 | 9.26% | $848.50 Million | $9.17 Billion | +3.77pp |
| 2003-12-31 | 5.48% | $521.11 Million | $9.50 Billion | -35.47pp |
| 2002-12-31 | 40.96% | $822.00 Million | $2.01 Billion | -2.28pp |
| 2001-12-31 | 43.23% | $744.07 Million | $1.72 Billion | -1.02pp |
| 2000-12-31 | 44.26% | $633.67 Million | $1.43 Billion | -2.51pp |
| 1999-12-31 | 46.76% | $597.62 Million | $1.28 Billion | -6.39pp |
| 1998-12-31 | 53.15% | $491.47 Million | $924.72 Million | +7.72pp |
| 1997-12-31 | 45.43% | $369.73 Million | $813.83 Million | +4.56pp |
| 1996-12-31 | 40.87% | $259.35 Million | $634.57 Million | -15.01pp |
| 1995-12-31 | 55.88% | $262.18 Million | $469.20 Million | -0.52pp |
| 1994-12-31 | 56.40% | $213.12 Million | $377.86 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more